Skip to content

Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care

Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00308724
Enrollment
148
Registered
2006-03-30
Start date
2004-03-31
Completion date
2015-04-30
Last updated
2024-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

Generalized Anxiety Disorder, Geriatric

Brief summary

The purpose of this study is to determine whether cognitive behavior therapy (CBT) is effective in the treatment of generalized anxiety disorder (GAD) in adults age 60 and older in a primary care setting.

Detailed description

Generalized Anxiety Disorder (GAD) is one of the most common anxiety disorders among older adults. Anxiety in older adults is associated with decreased physical activity, poorer self-perceptions of health, decreased life satisfaction, and increased loneliness. Because many older adults with anxiety seek assistance in a medical setting, treatment has been primarily pharmacological. There is, however, limited evidence of the effectiveness of psychotropic medications. Given the potential difficulties in prescribing psychotropic medications in later life (e.g., increased adverse effects, potential drug interactions), psychosocial treatments may be important alternative or adjuncts. The treatment phase of this study lasts 10 weeks, during which patients will be randomly assigned to either cognitive behavior therapy (CBT) or usual care. Follow-up will last 12 months after treatment completion, during which time patients will complete telephone assessments.

Interventions

BEHAVIORALCognitive Behavior Therapy

8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period

BEHAVIORALTelephone check-in

Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
National Institutes of Health (NIH)
CollaboratorNIH
The University of Texas Health Science Center, Houston
CollaboratorOTHER
Kelsey Research Foundation
CollaboratorOTHER
Kelsey-Seybold Clinic
CollaboratorOTHER
Michael E. DeBakey VA Medical Center
CollaboratorFED
Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Generalized Anxiety Disorder

Exclusion criteria

* Active suicidal intent * Current psychosis * Current bipolar disorder * Substance abuse within past month * Cognitive impairment

Design outcomes

Primary

MeasureTime frame
AnxietyBaseline and 3, 6, 9, 12 and 15 months

Secondary

MeasureTime frame
Quality of life inventory (QOLI)Baseline and 3, 6, 9, 12 and 15 months
Satisfaction with CBT and general health careBaseline and 3, 6, 9, 12 and 15 months
Service utilizationBaseline and 3, 6, 9, 12 and 15 months
Functional and health statusBaseline and 3, 6, 9, 12 and 15 months
Sleep qualityBaseline and 3, 6, 9, 12 and 15 months
Use of alcohol and other substancesBaseline and 3, 6, 9, 12 and 15 months
DepressionBaseline and 3, 6, 9, 12 and 15 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026